Gilead Science May Not Get Away With Their Truvada to Descovy Switch

Gilead may have intentionally postponed the development of Descovy to continue profiting from Truvada putting patient's lives at risk

Truvada Bone Lawsuit News

Friday, April 9, 2021 - At the center of the controversy surrounding AIDS management drugs is Gilead Science's handling of the transition from Truvada to the company's other drug Descovy (tenofovir alafenamide) for people living with AIDS and for people that take the drug to prevent HIV transmission. Descovy is thought to be safer and just as effective as Truvada and plaintiffs that have allegedly been injured by Truvada have filed lawsuits that accuse Gilead of deliberately keeping the safer drug off of the market to maximize their profits. Medical experts researching the topic agree that Gilead has overlooked patient safety and instead focused on their bottom line. According to, "HIV-prevention advocacy group, PrEP4All Collaboration, filed a petition with the U.S. Patent and Trademark Office (PTO) alleging that Gilead Sciences intentionally delayed the development of a safer HIV drug (Descovy)." PrEP4All's PTO petition requested that the agency reject Gilead's attempt to extend Truvada's patent on the grounds, "Gilead intentionally postponed the development of the drug to continue profiting from its older combination HIV drugs, Viread and Truvada, without competition from the newer, safer drug." If you or a loved one have been taking Truvada daily for many years and have developed osteoporosis or kidney failure, you should speak with a Truvada bone break lawyer and file a claim against the drug's manufacturer. Truvada lawsuit handled by experienced attorneys representing American's nationwide, offer a free consultation with no obligation to file a lawsuit claim.

Gilead Sciences is accused by plaintiffs of keeping Descovy off of the market and forcing patients to continue with Truvada. Remaining on Truvada allegedly caused patients to develop brittle bones that resulted in bone fractures during activities like walking or getting in or out of a car. Truvada patients also report kidney failure resulting in having to undergo dialysis treatments and kidney transplants. Truvada bone break and kidney failure lawyers are interviewing those who have been injured while taking Truvada to see if they qualify to file a claim for monetary compensation such as the replacement for lost wages, reimbursement of medical expenses, replacement of future wages, and punitive damages for their pain and suffering. Truvada's adverse side effects appear to have hit people living with AIDS (PLWA) especially hard since that group has relied on Truvada as a life-saving part of the anti-retroviral cocktail that has contained their disease, making life manageable.

Gilead is participating in the government's program of giving away 2 million bottles of Truvada free to patients that cannot afford the cost of the anti-HIV transmission drug. The company has seamlessly replaced Truvada with Descovy now that the former has gone off-patent. A generic version of Truvada went on the market on October 1, 2020, but the price has remained competitive with the $1800 price of Truvada or Descovy. Other countries offer Truvada and Descovy to their citizens for as little as $30 per year. To counter Gilead's greediness, United Health Care has decided not to cover the cost of Descovy for those switching from Truvada. Instead, the health insurance company will encourage the development of a broad range of cheaper generic alternatives.

More Recent Truvada Bone Lawsuit News:

No-Cost, No-Obligation Truvada Lawsuit Case Review If You or a Loved One Suffered from Truvada Bone or Kidney Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.